Tech Company Financing Transactions
A2 Biotherapeutics Funding Round
Nextech Invest, Samsara BioCapital and The Column Group participated in a $57 million Series A funding round for A2 Biotherapeutics. The round was announced on 11/6/2019.
Transaction Overview
Company Name
Announced On
11/6/2019
Transaction Type
Venture Equity
Amount
$57,000,000
Round
Series A
Proceeds Purpose
Proceeds purposes were not disclosed.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
30301 Agoura Rd. 210
Agoura Hills, CA 91301
USA
Agoura Hills, CA 91301
USA
Phone
Undisclosed
Website
Email Address
Overview
A2 is a biotechnology company, focused on cell therapy, that aspires to beat cancer via tumor-specific targeting. The company was founded in 2018 by Alexander Kamb, Michael Gallo and Paul Kang.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Scott Foraker
Chief Operating Officer
David Lucas
Chief Scientific Officer
Alexander Kamb
Browse more venture capital transactions:
Prev: 11/6/2019: Senreve venture capital transaction
Next: 11/6/2019: Riskified venture capital transaction
Share this article
About Our VC Transactions Data
We do our best to report on every notable VC transaction. VC transactions reported here are sourced from a variety of public sources. The data is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs